Long-acting injection a shot in the arm for GSK's HIV business
LONDON (Reuters) – A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business. FILE PHOTO: The GlaxoSmithKline (GSK) logo. March 21, 2018. REUTERS/Loriene Perera/File Photo GSK’s majority-owned ViiV Healthcare unit said on… Read More »